# FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

> **NCT03721653** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 218 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** L-Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03721653
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-30
- **Primary completion:** 2021-06-15
- **Final completion:** 2023-08-31
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721653, "FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03721653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*